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AbstrACt
Introduction Hepatitis C virus (HCV) is the second largest 
contributor to liver disease in the UK, with injecting 
drug use as the main risk factor among the estimated 
200 000 people currently infected. Despite effective 
prevention interventions, chronic HCV prevalence remains 
around 40% among people who inject drugs (PWID). 
New direct-acting antiviral (DAA) HCV therapies combine 
high cure rates (>90%) and short treatment duration 
(8 to 12 weeks). Theoretical mathematical modelling 
evidence suggests HCV treatment scale-up can prevent 
transmission and substantially reduce HCV prevalence/
incidence among PWID. Our primary aim is to generate 
empirical evidence on the effectiveness of HCV ‘Treatment 
as Prevention’ (TasP) in PWID.
Methods and analysis We plan to establish a natural 
experiment with Tayside, Scotland, as a single intervention 
site where HCV care pathways are being expanded 
(including specialist drug treatment clinics, needle and 
syringe programmes (NSPs), pharmacies and prison) and 
HCV treatment for PWID is being rapidly scaled-up. Other 
sites in Scotland and England will act as potential controls. 
Over 2 years from 2017/2018, at least 500 PWID will be 
treated in Tayside, which simulation studies project will 
reduce chronic HCV prevalence among PWID by 62% (from 
26% to 10%) and HCV incidence will fall by approximately 
2/3 (from 4.2 per 100 person-years (p100py) to 1.4 
p100py). Treatment response and re-infection rates 
will be monitored. We will conduct focus groups and 
interviews with service providers and patients that accept 
and decline treatment to identify barriers and facilitators 
in implementing TasP. We will conduct longitudinal 
interviews with up to 40 PWID to assess whether 
successful HCV treatment alters their perspectives on and 
engagement with drug treatment and recovery. Trained 
peer researchers will be involved in data collection and 
dissemination. The primary outcome – chronic HCV 
prevalence in PWID – is measured using information 
from the Needle Exchange Surveillance Initiative survey 
in Scotland and the Unlinked Anonymous Monitoring 
Programme in England, conducted at least four times 
before and three times during and after the intervention. 
We will adapt Bayesian synthetic control methods 
(specifically the Causal Impact Method) to generate 
strengths and limitations of this study
 ► Our control sites in the rest of Scotland and England 
were not randomised so there will be confounding 
and uncertainty in the intervention effect estimates.
 ► Hepatitis C virus treatment and prevention strategy 
in UK (and Europe) is evolving - motivated both by 
WHO ‘elimination targets’ and falling drug prices – 
which may contaminate our controls.
 ► However, our statistical models suggest that we 
should have sufficient power to detect an interven-
tion effect and can model changes over time.
 ► We will develop dynamic transmission and econom-
ic models that can estimate cost-effectiveness in-
cluding the prevention benefit of this intervention.
 ► We are conducting multiple nested qualitative stud-
ies and training and using peer researchers.
 o
n
 M
ay 7, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029538 on 24 September 2019. Downloaded from 
2 Hickman M, et al. BMJ Open 2019;9:e029538. doi:10.1136/bmjopen-2019-029538
Open access 
the cumulative impact of the intervention on chronic HCV prevalence 
and incidence. We will use a dynamic HCV transmission and economic 
model to evaluate the cost-effectiveness of the HCV TasP intervention, 
and to estimate the contribution of the scale-up in HCV treatment to 
observe changes in HCV prevalence. Through the qualitative data we will 
systematically explore key mechanisms of TasP real world implementation 
from provider and patient perspectives to develop a manual for scaling 
up HCV treatment in other settings. We will compare qualitative accounts 
of drug treatment and recovery with a ‘virtual cohort’ of PWID linking 
information on HCV treatment with Scottish Drug treatment databases to 
test whether DAA treatment improves drug treatment outcomes.
Ethics and dissemination Extending HCV community care pathways 
is covered by ethics (ERADICATE C, ISRCTN27564683, Super DOT C Trial  
clinicaltrials. gov: NCT02706223). Ethical approval for extra data collection 
from patients including health utilities and qualitative interviews has 
been granted (REC ref: 18/ES/0128) and ISCRCTN registration has been 
completed (ISRCTN72038467). Our findings will have direct National 
Health Service and patient relevance; informing prioritisation given to 
early HCV treatment for PWID. We will present findings to practitioners and 
policymakers, and support design of an evaluation of HCV TasP in England.
IntroduCtIon And bACkground
Infection with hepatitis C virus (HCV) is a progressive 
disease that over 20 to 40 years can lead to liver cancer and 
premature death. HCV is the second largest contributor 
to liver disease in the UK and one of the few causes that 
is curable.1 In the UK it is estimated that approximately 
200 000 people are infected with HCV, over 85% of whom 
are people who inject or have injected drugs (PWID).2–5 
Chronic HCV prevalence and incidence among PWID 
remains high in UK at 20% to 50% and 5 to 15 per 100 
person-years, respectively.4 6–18 Prevention of HCV trans-
mission among PWID is critical to long-term prevention 
of HCV related liver disease.19
We have reviewed the effectiveness of traditional 
primary prevention against HCV – opioid substitution 
treatment (OST) and needle and syringe programmes 
(NSPs).12 20–22 Ongoing exposure to OST and high-cov-
erage NSPs can reduce the risk of HCV transmission 
by 50% to 80%.12 22 In Scotland HCV incidence among 
PWID decreased from approximately 14 to 6 per 100 
person-years from 2008/2009 to 2011/2012 coinciding 
with the launch of the Scottish HCV strategy and action 
plan which incorporated scale-up of harm reduction 
interventions and HCV treatment.10 23 We estimated that 
60% of this decline could be attributed to the scale-up of 
OST and NSP during the action plan and that 1400 HCV 
infections were averted by 2015.24 However, there was no 
appreciable reduction in overall anti-HCV prevalence 
over this short period, and there is some suggestion that 
incidence has increased recently to ~10 per 100 person-
years (http://www. hps. scot. nhs. uk/ resourcedocument. 
aspx? id= 5863). HCV transmission models suggest that 
primary prevention through NSP and OST alone is insuf-
ficient to achieve substantial reductions (of the order of 
40% or more within 10 years) in HCV prevalence among 
PWID in the UK.25 26
Prevention of hepatitis C disease and HCV transmis-
sion is now possible because highly effective, tolerable, 
short-course interferon-free direct-acting antiviral thera-
pies (DAAs) are available for all HCV genotypes with cure 
rates – defined as sustained virological response (SVR) 
- exceeding 90%.27–29 We, and others, hypothesise that 
HCV treatment scale-up for PWID, and resulting HCV 
Treatment as Prevention (TasP) could enhance other 
primary interventions and reduce HCV incidence and 
chronic prevalence to negligible levels (ie, towards elimi-
nation as a major public health concern).30–35 TasP refers 
to the concept whereby future transmission is reduced by 
treating affected individuals36 37: in HIV TasP antiretro-
viral treatment reduces transmission because individuals 
have undetectable infection38 in HCV TasP people are 
cured so reducing opportunities for future transmission. 
WHO targets for HCV elimination, adopted by UK and 
other countries, aim to reduce HCV incidence by 80% 
and associated mortality by 65% by 2030.39–44
Clinical guidelines in Europe and USA changed from 
recommending prioritising HCV treatment to people 
with moderate-to-severe liver disease towards removing 
any restrictions and recommending that people at risk 
of transmission irrespective of fibrosis stage are offered 
treatment.45–49 Cost-effectiveness models that incorporate 
the population prevention benefit suggest early treatment 
should be prioritised to PWID over other patient groups 
(unless chronic HCV prevalence and transmission is very 
high).50 There is direct evidence that SVR following HCV 
treatment reduces liver disease progression and mortality 
risk,51–53 but in two recent reviews we found no empir-
ical evidence that HCV treatment scale-up has reduced 
chronic HCV prevalence and incidence in PWID popu-
lations.36 37 In part this is because in most settings HCV 
treatment rates in PWID are too low and any changes 
generally too small to be detected, as we show in two 
studies of seven sites in UK7 and an extension to 11 sites 
in Europe.54 Until very recently in the UK, the annual 
number of HCV DAA treatments was restricted - as drug 
costs could be expensive (>£10 000 per patient). There 
is the opportunity now to test whether scaling up HCV 
treatment will reduce chronic HCV prevalence and trans-
mission among PWID.44
In a pilot study (‘Eradicate C’) in Tayside we showed 
that we can increase HCV case-finding and engage and 
successfully treat PWID in the community.55 Combining 
further studies on extending community HCV treatment 
pathways in Tayside and additional treatments provided 
by National Health Service (NHS) Tayside and Scot-
tish Government we can establish an immediate natural 
experiment (with Tayside as the intervention site and 
other sites in Scotland and England as controls) to test 
and generate UK empirical evidence on the and potential 
impact and cost-effectiveness of HCV TasP in PWID. The 
UK is one of few countries worldwide to have an estab-
lished nationwide surveillance system monitoring HCV 
infection among PWID.9 12 17 22 56–60 This is undertaken 
through a series of cross-sectional voluntary anonymous 
surveys of PWID recruited at harm reduction services, 
referred to as the Unlinked Anonymous Monitoring 
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Figure 1 Overview of HCV testing and treatment pathways for the PWID population in NHS Tayside. DBS, dried blood spot; 
HCV, hepatitis C virus; NHS,National Health Service; OST, opioid substitution treatment; PWID, people who inject drugs.
Programme (UAM) in England and Wales and the Needle 
Exchange Surveillance Initiative (NESI) in Scotland.61 62 
In addition, the UK has established sentinel laboratory 
surveillance of HCV testing and national monitoring of 
HCV treatment.8 63–65 The data collected in both UAM 
and NESI will be used to assess out outcome.
Alongside a natural experiment in Tayside, we will 
collect information to assess the treatment facilitators 
and barriers. Historically it has proven very hard to 
engage PWID in HCV treatment.66–69 Some barriers to 
engagement, such as poor efficacy or fear of interferon 
treatment side-effects, may be ameliorated by DAA 
therapy. However, other barriers such as mistrust of 
health services, stigma and competing priorities faced 
by PWID may persist. In addition, providers may be reti-
cent to refer or provide HCV treatment to PWID due to 
concerns about adherence, reinfection and perceptions 
of treatment ‘worth’.70 71 It is expected that co-locating 
HCV treatment within existing services will reduce many 
system and provider level barriers to PWID accessing 
care.66–68 72–77 However, this has not been tested in the 
context of community wide scale-up of interventions 
across multiple potential pathways. It is critical, therefore, 
that we understand how HCV TasP is embedded within 
the existing service landscape and incorporated into 
providers’ professional roles.
Finally it has been hypothesised that successful HCV 
treatment in PWID may positively impact on under-
standings of self and identity and improve treatment of 
drug use disorders.71 72 78–80 Accounts of ‘transformative’ 
outcomes extending beyond viral clearance alone include 
reference to reductions in drug and alcohol use, uptake 
of safer injecting practices, improved social relationships, 
enhanced sense of responsibility and self-worth. Hints 
of such collateral or indirect benefits are also found in 
quantitative studies reporting low re-infection rates and 
reductions in risky injecting behaviours among treated 
PWID.81 82 We aim to test this hypothesis in our qualitative 
follow-up study and compare the findings to quantitative 
data generated from a virtual cohort.
MEthods And AnAlysIs
study design
Our intention is to create and conduct a mixed methods 
study, including qualitative studies and economic evalua-
tion, of a natural experiment of HCV TasP among PWID. 
We also will develop methods for evaluating HCV TasP.
Methods
Scaling-up HCV treatment
The intervention comprises the scale-up of HCV treat-
ment in PWID which has started early in Tayside. By 
combining support from Scottish Government, National 
Health Board Tayside (NHS Tayside) and industry (MSD, 
Gilead, BMS) we can deliver rapid intensive scale-up of 
HCV treatments for PWID (comprising an extra 400 HCV 
treatments, a 3.5-fold increase from treatments for PWID 
prior to April 2017, see sample size below). We have devel-
oped multiple integrated community HCV care path-
ways, including novel care pathways in pharmacies, a low 
threshold NSP, drug treatment services and prisons (see 
figure 1). Our diagnostic pathways make extensive use 
of dried blood spot (DBS) testing for diagnosis of HCV 
antibody and chronic HCV with subsequent conventional 
laboratory testing in preparation for treatment (viral 
load, liver function and FIB-4 fibrosis score).83–85
Study population
Our intervention is delivered and measured at the 
population level – which we have created by combining 
several individual studies and treatment pathways as 
shown in figure 1 (see ethics section below for the indi-
vidual studies). We gained ethical approval from East 
of Scotland Research Ethics Service REC 1 (ref: 18/
ES/0128) to ask patients for permission to be recruited 
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Figure 2 Trends in HCV antibody prevalence among PWID in Scotland and England 2010/2011 to 2016. HCV, hepatitisC virus; 
PWID, people who inject drugs.
into the qualitative study (below) and extended clinical 
and behavioural drug history and data on health utilities 
(EQ5D-5L) at onset of treatment, during treatment and 
after the end of treatment.
Community HCV specialist nurses (3.5 full-time equiv-
alent (FTE)) coordinate and deliver case-finding and 
treatment across the pathways in Tayside (figure 1).
The region of Tayside co-localises to NHS Tayside 
which is the provider of healthcare to a geographical area 
of 2903 sq mi (7519 km2) including the cities of Dundee 
and Perth and the counties of Angus and Perth & Kinross, 
situated in the east of Scotland with a population of 
416 000. It is a mixture of urban and rural environments 
with some of the most affluent and most deprived areas 
in Scotland. It is therefore a representative microcosm of 
many areas in the UK.
HCV treatment
Apart from expansion of community HCV care pathways, 
no new clinical procedures will be investigated and all 
PWID with chronic HCV will be offered oral DAA HCV 
treatment compliant with the Scottish clinical guidelines 
(https://www. hps. scot. nhs. uk/ resourcedocument. aspx? 
id= 6621).
As per local standard of care, participants will be offered 
appropriate harm reduction advice.
Standard care for patients is to test for SVR at 12 weeks 
after end of treatment with patients being recommended 
for annual follow-up if at risk of re-infection. Specialist 
nurses concentrate on building a good relationship with 
the participant to ensure that they do return for follow-up 
appointments. Health Protection Scotland collates 
national public health surveillance data on the number, 
characteristics and response of patients initiated onto 
HCV therapy, through Clinical Databases installed in 17 
specialist HCV treatment centres, across Scotland.41 86 A 
similar system also is available in England.
HCV surveillance and intervention outcome (chronic HCV in PWID)
The outcome is chronic HCV prevalence (HCV viraemia 
as measured by HCV PCR) among PWID in the commu-
nity (not just in the patients who undergo HCV treat-
ment). Prevalence will be monitored using the NESI and 
UAM surveys, as detailed below. During 2017 to 2022, 
three waves of data collection for NESI (n=7500) and five 
to six for UAM (n=17 000 in England) will measure this 
outcome.
In our pre-intervention period from 2010/2011 to 
2016 there have been four NESI surveys in Scotland 
(n=10 000 participants in total) and six UAM surveys in 
England (n=16 000 in total), which have involved the 
collection of DBS linked to questionnaire data. Partici-
pants are recruited at sentinel sites by a team of trained 
interviewers in Scotland (at over 100 NSP sites) and by 
agency staff in over 60 low-threshold drug agencies across 
England.58 61 Participants complete a short questionnaire, 
with common questions across UAM and NESI, on demo-
graphics, injecting behaviour and service utilisation, and 
importantly (in relation to quantifying the intervention 
effect) both survey approaches have remained consistent 
over time.
The DBS samples collected in NESI and UAM have all 
been tested for HCV antibody, using the same methods 
(where sensitivity and specificity of the assay on DBS are 
close to 100%),83 84 and illustrate that antibody prevalence 
(ever infection) has remained relatively stable among 
PWID during this time (figure 2). PCR positivity among 
antibody positive samples is used to determine chronic 
infection.
All NESI and UAM samples will be tested for HCV anti-
body and RNA PCR to assess the impact of HCV therapy 
scale-up – which is critical as trends in chronic infec-
tion and antibody status will diverge as more people are 
cured. In addition, we will undertake RNA PCR testing 
of all historical samples that were HCV antibody posi-
tive shown in figure 2 so that we can measure chronic 
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Figure 3 Projected chronic HCV prevalence and incidence among PWID in Tayside with and without the intervention. Blue 
shaded area denotes the 95% credibility intervals of the model projections with and without the intervention. HCV, hepatitisC 
virus; PWID, people who inject drugs; py,person-years.
HCV prevalence among PWID pre-intervention, as well as 
post-intervention, for analysis (below)
Data on HCV PCR positivity among antibody negative 
samples identify recent infections and is used to estimate 
HCV incidence – which has fluctuated between 5 to 10 
infections per 100 person-years across the UK during the 
last 5 years.61 We will also estimate HCV incidence from 
our transmission dynamic models.24 54
sample size, power and estimating intervention effect
We updated estimates of the prevalence of PWID in 
Tayside5 which suggest there are 2760 (95% Cred-
ible Interval, CrI 2360 to 3170) PWID either currently 
injecting and/or in OST. NESI data suggest that approx-
imately 30% have chronic HCV and over 75% of PWID 
with chronic HCV have been diagnosed. Prior to 2017 
approximately 66 PWID were treated annually. From 
April 2017 we plan to treat at least 500 PWID in Tayside 
over 2 years (as a result of expanded community care 
pathways shown in figure 1 and extra HCV treatments 
provided by NHS, Scottish Government and Industry 
funding). Adapting a transmission dynamic model that 
has been used in Tayside,87 we hypothesise that within 
2 years chronic HCV prevalence among PWID will reduce 
by approximately 62% from 26% (95% CrI 20 to 32) 
to at least 10% and chronic HCV incidence will fall by 
approximately 2/3 s from 4.2 (95% CrI 2.4 to 7.1) per 100 
person-years (p100py) to 1.4 (95%CrI 1.0 to 1.4) p100py 
(as shown in figure 3). Modelling also suggests that main-
taining these reductions after 2019 will require less than 
40 treatments per year.
We will adapt the Causal Impact synthetic control Model 
(CIM) as proposed by Brodersen and colleagues.88 89
We have performed simulation studies to test power 
and evaluate the utility of the CIM assuming informa-
tion on chronic HCV prevalence among PWID (shown 
in figure 4). Provided trends in the chronic HCV prev-
alence in the pre-intervention period are relatively 
stable (which is the case) there will be sufficient power 
to detect the projected reduction in chronic prevalence. 
For example, in figure 4d we see that for a prevalence 
reduction of 40% by year 2 to 3 the credible intervals of 
the estimated cumulative effect (cumulative drop in prev-
alence) exclude zero, correctly identifying evidence of a 
successful intervention. Whereas a cumulative reduction 
of <20% is unlikely to be detected.
Qualitative studies
Understanding the barriers and facilitators to scaling-up 
community-based HCV treatment
The qualitative study design has two distinct arms 
focusing on the intervention providers, and the interven-
tion recipients.
Intervention providers
A purposive sample of 30 intervention providers, 
comprising nursing leads and key individuals from collab-
orating organisations will be approached directly by the 
lead hepatitis nurse. Seven focus groups will be convened 
according to professional role and locality:
 ► HCV healthcare specialists (nurses and physicians).
 ► Community pharmacists.
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Figure 4 Causal impact synthetic control method (CIM) 
simulation and estimated intervention effects and 95% 
credible intervals for a range of assumed effects. Footnote: 
Illustration of CIM. First subplot shows a single data set, 
where solid lines represent the simulated prevalence in the 
absence of the intervention, and the dashed lines represent 
the outcome of treated site in the post-intervention period 
under different intervention magnitude scenarios. For each 
one of the three scenarios,we calculate the estimated 
average intervention effect along with credible intervals. 
These are shown in subplots 2 to 4. We see that as the effect 
increases, the intervals tend to move away for zero. However, 
the intervention effect only becomes significant in scenario 3, 
where zero is not included in any of the post-intervention time 
points.
 ► Prison staff (both healthcare and security).
 ► ‘Drug workers’ (from OST and NSP services).
Each focus group will consist of a maximum of six indi-
viduals and ideally comprise multi-agency mixed groups. 
Individual interviews by telephone will be offered for those 
hesitant to join a group (estimate 10 interviews). Topic 
guides informed by previous work in this area66 68 76 90 will 
facilitate group discussion.
Intervention recipients – cross-sectional and longitudinal
The intervention recipient arm of the study will comprise 
both cross-sectional and longitudinal elements. A 
cross-sectional approach will be employed to recruit 6 
to 10 participants who do not take up the offer of treat-
ment. These individuals will be recruited through the 
treatment pathways or through our peer-researcher 
networks. The longitudinal element will follow a cohort 
of up to 40 individuals recruited following their course 
of HCV treatment. These individuals will be purposively 
sampled from the existing services in which HCV TasP has 
been embedded (ie, pharmacy, prison and drug service), 
and then followed-up at 1 year post-treatment (with 70% 
expected to be followed-up).91 We aim to recruit women 
as well as men, younger and older people; those treated 
previously and first time; those injecting and not injecting 
at treatment onset. Follow-up interviews will explore 
collateral effects of HCV TasP including outcomes 
pertaining to drug use and injecting practices (secondary 
outcome below).
Participants will be recruited by hepatitis nurses or other 
clinical staff in Tayside and the face-to-face semi-structured 
interview will be conducted by peer-researchers, trained 
and guided by experienced qualitative researchers. Dr 
Magdalena Harris explains the importance of the use of 
peer researchers within the context of EPIToPe: https://
www. youtube. com/ watch? v= 9ZZo3fKOXlg.92 93 The Scot-
tish Drugs Forum (SDF) works with a group of Tayside 
peer-researchers with lived experience of injecting. 
Peer-researchers will receive study-orientated training 
and be provided with ongoing support to co-produce data 
and contribute to study outputs. A £20 shopping voucher 
will be offered to all interviewees except those in prison 
(Scottish prison service ethics did not permit thank you 
vouchers to prison participants).
Qualitative data analysis
Interviews and focus-groups will be audio-recorded using 
encrypted digital voice recorders, transcribed verbatim 
and anonymised. Nvivo v.10 software will be used to code 
and manage qualitative data. First level analysis will be 
deductive, guided by the research questions, and peer 
researchers will be consulted for input and feedback 
during the analytical process.94 A constant comparison 
method will be used to develop the thematic analysis 
and will reflect diverging and converging narratives, 
for example, across groups of intervention recipients 
at different time points in the treatment pathway, or 
between groups of intervention providers.94 The find-
ings will be contextualised in the relevant theoretical 
perspectives which may include the diffusion of preven-
tive innovations (staff) or social norms and values that 
might underpin health behaviour (recipients).95 96 We 
will assess TasP both from the providers’ perspective and 
from patients’ perspective including those who refuse 
treatment.
We will use the findings iteratively to update the HCV 
TasP logic model shown in figure 5. Our qualitative data 
will be used to generate a manual of an optimal interven-
tion for other sites in UK. In previous examples, such as 
(https://www. youtube. com/ channel/ UCBV8smLmkO-
QVT9D0OR- md1g/ videos) we have used the Behaviour 
Change Wheel96 as the framework to retrospectively 
analyse the success and failure of implementation within 
Tayside and then prospectively to formulate the optimal 
implementation intervention.
Mixed method study on drug use outcomes: ost retention, 
drug overdose, recovery and social transformation
Health Protection Scotland (HPS) link data on diag-
nostic HCV tests in the four largest Scottish NHS boards 
(including Tayside)8 and all persons undergoing HCV 
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Figure 5 Preliminary logic model HCV treatment as prevention (EPIToPe). HCPs, healthcare providers; HCV, hepatitis C virus; 
HCWs,healthcare workers; Hep-C, hepatitis C; NHS, National Health Service; NSP,needle and syringe programmes; TasP, 
Treatment as Prevention; PWID, people who inject drugs.
treatment in the Scottish HCV Clinical database97 which 
are also linked with other databases (including deaths, 
hospitalisations and drug treatment)8 42 98–100 and from 
2018 Scotland's Prescribing Information System which 
holds data on OST and NHS prison health database 
(Prison Vision).101–105 PWID attending drug services who 
were HCV diagnosed, compared with those who were not, 
are at increased risk of drug-related and other cause-spe-
cific morbidity/mortality.106 107 Thus, we will create a 
virtual cohort of chronic HCV infected PWID (estimated 
to involve at least 600 individuals from Tayside and 3000 
from elsewhere) and through linkage identify those who 
have been treated and attained SVR with those who have 
not. We will assess and compare the following outcomes: 
retention in drug treatment (determined through linkage 
to drug treatment and prescribing databases), drug-re-
lated and alcohol-related morbidity/mortality (through 
linkage to all hospital admission and mortality databases) 
and other markers of relapse (through linkage to prisons 
database).
Economic and impact evaluation
Infectious disease models can test the extent to which 
observed changes in disease transmission can be attributed 
to specific interventions,108–112 and assess cost-effective-
ness of interventions that avert secondary infections, that 
is, have a population prevention benefit.50 85 113–117 We will 
update and adapt a transmission model of HCV among 
PWID in Scotland and Tayside to model the impact of 
the HCV treatment intervention based on historical 
trends and new observations collected as part of this 
programme.39 87 We will stratify the PWID population into 
current (injected in the previous year) and temporarily 
ceased (in OST and not injected in the previous year); 
as well as by duration of injecting (<3 years, 3 to 9 years, 
10+years since onset), prevention intervention exposure 
(OST and/or high coverage NSP), and intervention 
settings for testing and treatment. We will use Approx-
imate Bayesian Computation to calibrate the model 
to pre-intervention trends in chronic HCV prevalence 
and incidence among PWID in Tayside. The model will 
simulate the impact of observed rates of HCV treatment 
and cure rates for the intervention period, also incorpo-
rating any changes in the coverage of OST and NSP and 
injecting risk behaviours.
We will test consistency between the model impact 
projections and observed changes in HCV chronic prev-
alence and incidence from Tayside to disentangle the 
impact of HCV TasP from other interventions (OST/
NSP) or epidemiological changes, and predict the impact 
of the TasP on number of HCV infections averted. If 
they are not consistent then alternative evidence-based 
hypotheses will be tested for why the model projects a 
different impact and the best fitting models will then be 
used to project the impact of the intervention. This will 
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be assessed compared with two alternative counterfactuals 
where treatment rates are either at pre-scale-up levels in 
Tayside or at the average level achieved in other UK sites 
over the scale-up period. The impact of any changes in 
OST and NSP coverage will also be assessed to determine 
the contribution of those changes on observed effects. 
Impact will be assessed in terms of the relative decrease 
in prevalence and incidence, as well as the number and 
per cent of infections averted in the intervention model 
projections compared with each counterfactual over 
different time frames. These model projections can also 
be taken forward to evaluate the possible impact of the 
intervention over next 5 or 10 years.
We will evaluate the cost-effectiveness of the interven-
tion (HCV treatment scale-up) compared with status 
quo (expected rate of HCV case-finding and treatment 
among PWID in the rest of the UK) from a healthcare 
provider (NHS) perspective, with the cost-effectiveness 
of the different settings where case-finding occurs also 
being assessed. The cost-effectiveness model will be based 
on the same dynamic impact model, adapted to include 
HCV disease progression stages and tracking of health 
outcomes among PWID after cessation of injecting.50 The 
economic evaluation will incorporate both individual 
benefits of HCV treatment (on disease progression) as 
well as population benefits (on HCV transmission). We 
will calculate the total number of infections and deaths 
over a 50 year time horizon for the intervention and 
counterfactual scenario and estimate the costs and qual-
ity-adjusted life years (QALYs) based on the number of 
individuals in each disease stage per year in the model. 
We will discount all future costs and QALYs at 3.5% (The 
National Institute for Health and Care Excellence (NICE) 
guidelines https://www. nice. org. uk/ process/ pmg9/ 
resources/ guide- to- the- methods- of- technology- appraisal- 
2013- pdf- 2007975843781). Probabilistic sensitivity anal-
yses will be used to estimate the parametric uncertainty in 
the impact and cost projections. Cost-effectiveness results 
will be expressed in terms of incremental cost-effective-
ness ratios and net monetary benefits estimated using 
NICE thresholds (£20 000 and £30 000 per QALY). We will 
plot cost-effectiveness acceptability curves to determine 
the probability of the intervention being cost-effective 
compared with different willingness-to-pay thresholds. 
Analyses of covariance methods will be used to summarise 
the proportion of the variability in the incremental costs 
and QALYs explained by uncertainty in different input 
parameters. Univariate sensitivity analyses will consider 
the effect of changes in important parameters such as 
time horizon, treatment cost and discount rate.
We focus on the incremental or additional resource 
costs associated with the intervention in Tayside. These 
costs, in part based on our earlier work for other studies, 
will include such things as the nurse time spent on inter-
vention related activities (training other staff to offer HCV 
testing and treatment referral) as well as additional HCV 
testing and treatment costs, any additional OST costs due 
to HCV testing or treatment, and other staff time at the 
NSP, drug treatment centres and prisons involved with the 
intervention. Most of the incremental costs can be defined 
as variable (driven by extra nurse time and HCV testing/
treatment costs). NHS HCV care costs and health utilities 
will be attached to each disease stage, based primarily on 
previous syntheses and models, which assume that PWID 
have a lower quality of life (QoL) than non-PWID of a 
similar age, gender and liver disease stage.118–120 Addi-
tional data using the EQ-5D-5L tool during this study will 
generate new health utility data on the QoL among PWID 
before and after DAA treatment.
Patient and public involvement
Patient and public involvement (PPI) was led by the 
Hepatitis C Trust and supported by qualitative research 
assessing barriers and facilitators to HCV treatment access 
(led by Dr Magdalena Harris). The SDF were also actively 
involved in the development of EPIToPe. The input from 
PPI groups has influenced the design of care pathways 
and has ensured that peer research is an essential element 
of the qualitative strand of EPIToPe.
A pilot National Institute for Health Research (NIHR) 
funded study in England (HEPCAT) responding to NICE 
Guidance on Hepatitis Case Finding was co-designed with 
Hepatitis C trust. It showed that Hepatitis C Facilitators 
and peer-support networks can increase the uptake of 
HCV case-finding and HCV treatment readiness in addic-
tion services. This pilot study and our studies in Dundee/
Tayside will influence how HCV treatment can be scaled 
up in England and our proposed evaluation HCV treat-
ment as prevention.
Peer researchers will be trained to conduct the longi-
tudinal study with PWID treated for HCV and will be 
involved and contribute to the analysis of the findings. 
Peer researchers and SDF will be members of the project 
management group and steering committee.
Dissemination events will be held in Dundee to discuss 
and present the findings from the qualitative studies 
with patient groups and services. These will be facilitated 
by SDF to support active contribution from our peer 
researchers. The study findings will be summarised and 
promoted through SDF website, social media platforms 
and through their sector-wide conferences in Scotland. 
Hepatitis Scotland, who are hosted within SDF, together 
with patient and public groups in England will take an 
active role in the wider national and international dissem-
ination of the research, it’s translation into patient mean-
ingful materials and its integration into a national policy 
context. The research will also be promoted via Hepatitis 
C Trust and Public Health England.
dIsCussIon
strengths and limitations of this study
Several limitations arise from the ‘natural experi-
ment’ design as our intervention and controls were not 
randomised. In the UK and many other countries there is no 
longer sufficient equipoise in clinicians and policymakers 
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– given WHO and national strategies on HCV ‘elimina-
tion’ – to mount an randomised controlled trial of HCV 
TasP. As a result, there will be confounding and additional 
uncertainty in the measurement of the intervention effect. 
However, we consider that a natural experiment and use of 
synthetic control methods to be a more robust design than 
simple before and after studies. Our preliminary simulation 
work also suggests that we should have sufficient power to 
detect the large intervention effect that is planned.
We know also that HCV treatment and prevention 
strategy in UK (and Europe) is evolving – motivated both 
by WHO ‘elimination targets’ and falling drug prices 
– and our control sites in Scotland and England may 
increase HCV treatment rates earlier than expected. This 
will complicate the analyses a little and potentially dilute 
the intervention effect. We are confident that we can 
adapt the synthetic control methods to take account of 
changes over time – and that because Tayside has started 
so early in scaling up HCV treatment that we will have 
time to detect a difference in the outcome.
The lack of randomised controls means that we have 
to generate the counterfactual of ‘no HCV treatment 
scale-up’ through our HCV transmission model so that 
we can subsequently estimate cost-effectiveness of the 
intervention in Tayside. This is not ideal but has become 
standard practice in economic models of novel HCV 
treatment interventions – and we are involved with the 
modelling of HCV treatment pathways through homeless 
centres, prison, Accident and Emergency (A&E), phar-
macies, specialist drug clinics and NSPs (P Vickerman 
personal communication and for example55 85 121). We 
know also, however, that the benefit in terms of addi-
tional Quality of Life Years and averted HCV infections 
accrues and occurs over a prolonged period.50 It is more 
critical for any economic evaluation of HCV interven-
tions in PWID that a dynamic model is used so that the 
prevention benefit (in terms of HCV infections averted) 
is correctly accounted for.
We are using peer researchers in the qualitative arm 
of patients’ perspectives on the intervention and on the 
impact of HCV treatment on addiction outcomes. This is 
novel but adds additional challenges to obtaining NHS 
passports and ensuring data quality across the interviews 
and interviewees. We are also intending to support peers in 
analysis and interpretation of the findings which we believe 
has not been done before. We have trained the interviewers 
and will be monitoring their performance of the inter-
viewers to ensure consistent study quality – and will replace 
peers with our qualitative researcher if required.
Future study: natural experiment of tasP in England
In England HCV treatment is delivered through 22 oper-
ational delivery networks (ODNs). NHS England’s HCV 
strategy (2016 to 2019) prioritised 10 000 patients per 
year in line with the declared priorities of the network 
which could (and in many cases did) include people who 
use drugs at risk of transmission.44 In October 2018 it is 
anticipated that a new procurement deal will substantially 
increase the number of patients who can access DAAs 
and this will enable ‘trace and treat’ options to be intro-
duced. We will use the first part of EPIToPe including the 
manual generated by the qualitative study, enhancements 
to historical and ongoing surveillance of chronic HCV 
in PWID, infectious disease models and methodological 
developments of causal impact model, to co-design with 
ODN leads a natural experiment of HCV TasP in England.
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